GlobeNewswire Inc.··NaTelix Pharma's TLX591-Tx Clears Phase 3 Safety Hurdle, Paves Path to Expansion
Telix Pharmaceuticals' TLX591-Tx meets Phase 3 safety objectives in prostate cancer trial, advancing toward U.S. expansion with FDA.
TLXPhase 3 clinical trialFDA approval